The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Open accessAbstract
BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare Oncology Agnostic Research (ROAR) basket study. We report an updated analysis describing the efficacy and safety of dabrafenib plus trametinib in the full ROAR ATC cohort of 36 patients with ∼4 years of additional study follow-up. PATIENTS AND METHODS: ROAR (NCT02034110) is an open-label, nonrandomized, phase II basket study evaluating dabrafenib plus trametinib in BRAF V600E-mutant rare cancers. The ATC cohort comprised 36 patients with unresectable or metastatic ATC who received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints were duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: At data cutoff (14 September 2020), median follow-up was 11.1 months (range, 0.9-76.6 months). The investigator-assessed ORR was 56% (95% confidence interval, 38.1% to 72.1%), including three complete responses; the 12-month DOR rate was 50%. Median PFS and OS were 6.7 and 14.5 months, respectively. The respective 12-month PFS and OS rates were 43.2% and 51.7%, and the 24-month OS rate was 31.5%. No new safety signals were identified with additional follow-up, and adverse events were consistent with the established tolerability of dabrafenib plus trametinib. CONCLUSIONS: These updated results confirm the substantial clinical benefit and manageable toxicity of dabrafenib plus trametinib in BRAF V600E-mutant ATC. Dabrafenib plus trametinib notably improved long-term survival and represents a meaningful treatment option for this rare, aggressive cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“3,37 Noting the caveats of cross-trial comparison, the ORR observed with vemurafenib in a phase II basket trial of that agent in patients with ATC was 29%, 37 substantially lower than the ORR observed with the dabrafenib plus trametinib combination therapy in the current report.”
Self-citationFive-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Self-citationPlanchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Self-citationEfficacy of Selpercatinib in RET -Altered Thyroid Cancers
Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 790
Self-citationBible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Self-citationSubbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30321-1 · Cited by 533
Self-citationAnaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 369
Self-citationPD-1 Blockade in Anaplastic Thyroid Carcinoma
Capdevila, J., Wirth, L. J., Ernst, T., Ponce Aix, S., Lin, C.-C., Ramlau, R., Butler, M. O., Delord, J.-P., Gelderblom, H., Ascierto, P. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02727 · Cited by 353
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
Self-citationSalama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 308
Dierks, C., Seufert, J., Aumann, K., Ruf, J., Klein, C., Kiefer, S., Rassner, M., Boerries, M., Zielke, A., la Rosee, P., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0322 · Cited by 254
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Saini, S., Tulla, K., Maker, A. V., Burman, K. D., & Prabhakar, B. S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0903-0 · Cited by 244
Wang, J. R., Zafereo, M. E., Dadu, R., Ferrarotto, R., Busaidy, N. L., Lu, C., Ahmed, S., Gule-Monroe, M. K., Williams, M. D., Sturgis, E. M., et al. (2019) · Thyroid® · doi:10.1089/thy.2019.0133 · Cited by 230
Self-citationPhase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Savvides, P., Nagaiah, G., Lavertu, P., Fu, P., Wright, J. J., Chapman, R., Wasman, J., Dowlati, A., & Remick, S. C. (2013) · Thyroid · doi:10.1089/thy.2012.0103 · Cited by 219
Lenvatinib for Anaplastic Thyroid Cancer
Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00025 · Cited by 205
Ragazzi, M., Ciarrocchi, A., Sancisi, V., Gandolfi, G., Bisagni, A., & Piana, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/790834 · Cited by 187
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1520 · Cited by 175
McFadden, D. G., Vernon, A., Santiago, P. M., Martinez-McFaline, R., Bhutkar, A., Crowley, D. M., McMahon, M., Sadow, P. M., & Jacks, T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404357111 · Cited by 166
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma
Rao, S. N., Zafereo, M., Dadu, R., Busaidy, N. L., Hess, K. R., Cote, G. J., Williams, M. D., William, W. N., Sandulache, V. C., Gross, N. D., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0395 · Cited by 154
Self-citationSosa, J. A., Elisei, R., Jarząb, B., Balkissoon, J., Lu, S.-P., Bal, C., Marur, S., Gramza, A. W., Ben‐Yosef, R., Gitlitz, B. J., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0078 · Cited by 151
A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer
Takahashi, S., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0557 · Cited by 150
Wirth, L. J., Brose, M. S., Sherman, E. J., Licitra, L. F., Schlumberger, M. J., Sherman, S. I., Bible, K. C., Robinson, B. G., Rodien, P., Godbert, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03093 · Cited by 134
Self-citationA Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer
Ha, H. T., Lee, J. J., Urba, S. G., Koenig, R. J., Sisson, J. C., Giordano, T. J., & Worden, F. P. (2010) · Thyroid · doi:10.1089/thy.2010.0057 · Cited by 129
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma
Iyer, P. C., Dadu, R., Ferrarotto, R., Busaidy, N. L., Habra, M. A., Zafereo, M., Gross, N. D., Hess, K. R., Gule-Monroe, M. K., Williams, M. D., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0285 · Cited by 125
Self-citationRole of BRAF in Thyroid Oncogenesis
Caronia, L. M., Phay, J. E., & Shah, M. H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1155 · Cited by 118
Smallridge, R. C., Copland, J. A., Brose, M. S., Wadsworth, J. T., Houvras, Y. J., Menefee, M. E., Bible, K. C., Shah, M. H., Gramza, A. W., Klopper, J. P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1106 · Cited by 114
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
Tirrò, E., Martorana, F., Romano, C., Vitale, S. R., Motta, G., Gregorio, S. D., Massimino, M., Pennisi, M. S., Stella, S., Puma, A., et al. (2019) · Genes · doi:10.3390/genes10090709 · Cited by 111
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Al-Jundi, M., Thakur, S., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Cancers · doi:10.3390/cancers12082104 · Cited by 111
Recent advances in the management of anaplastic thyroid cancer
Leo, S. D., Trevisan, M., & Fugazzola, L. (2020) · Thyroid Research · doi:10.1186/s13044-020-00091-w · Cited by 87
Lee, D. Y., Won, J., Choi, H. S., Park, D. J., Jung, K. C., Sung, M., Kim, K. H., Hah, J. H., & Park, Y. J. (2016) · Thyroid · doi:10.1089/thy.2016.0147 · Cited by 47
1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer
Cabanillas, M. E., Drilon, A., Farago, A. F., Brose, M. S., McDermott, R., Sohal, D., Oh, D.-Y., Almubarak, M., Bauman, J., Chu, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1404 · Cited by 33
Self-citationKeam, B., Kreitman, R. J., Wainberg, Z. A., Cabanillas, M. E., Cho, D. C., Italiano, A., Stein, A., Cho, J. Y., Schellens, J. H. M., Wen, P. Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy302.002 · Cited by 21
Self-citationResponse to Targeted Therapy inBRAFMutant Anaplastic Thyroid Cancer
Agarwal, R., Wang, J., Wilson, K. M. O., Barrett, W. L., & Morris, J. C. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0130 · Cited by 18
Arıkan, R., Telli, T. A., Demircan, N. C., Başoğlu, T., Erçelep, Ö., Atasoy, B. M., Özgüven, S., Dane, F., & Yumuk, P. F. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100668 · Cited by 11
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
Fazeli, S., Paal, E. E., Maxwell, J. H., Burman, K. D., Nylén, E., & Khosla, S. (2019) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709619890942 · Cited by 9
Bueno, F., Abelleira, E., von Stecher, F., de Lima, A. P., & Pitoia, F. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000325 · Cited by 4
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Boucai, L., Zafereo, M., & Cabanillas, M. E. (2024) · JAMA · doi:10.1001/jama.2023.26348 · Cited by 701
Self-citationChen, D. W., Lang, B. H. H., McLeod, D. S. A., Newbold, K., & Haymart, M. R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00020-x · Cited by 590
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Metadata
- Authors
- Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., & Keam, B.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 33
- Issue
- 4
- Pages
- 406-415
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4205515761
- Cited by
- 357
- References
- 42
- FWCI
- 42.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.